# Devil's Advocate — Phase 2 report

## Strongest counter-argument (≈250 words)
The paper's two findings may both be artefacts of how the treatment is measured. If LSEG adds firms in batches
and then fills in several years of historical scores, the observed "first scored year" is earlier than the year in
which investors could see a score. The pre-coverage window in Figure 1 would then partly overlap the true
selection window (the period in which the firm grew into the vendor's universe), and the post-coverage window would
include years before any score was public. Under this reading the run-up is not evidence that "coverage follows
value" in real time; it is evidence that the vendor's universe is defined by size, which Table 1 already shows.
Further, the post-coverage null cannot be read as "no effect": with a strong pre-trend and a failing placebo, the
counterfactual is not identified, and a positive effect offset by mean reversion after a run-up is observationally
equivalent. The title's claim is therefore stronger than the design supports unless the authors (i) discuss
backfilling and its bias, (ii) show that the null is not driven by reversal after the run-up (condition on pre-
growth or use trend-robust estimates), and (iii) phrase the conclusion as an ordering of events in the observed
data rather than a behavioral statement about the provider.

## Issue list
- DA-1 MAJOR [D3] Backfilled/rewritten scores can shift the treatment date (Section 2.1). Location: treatment
  definition. Fix: discuss; state direction of bias; soften provider-behaviour language.
- DA-2 MAJOR [D3] Post-coverage null is not interpretable without a sensitivity analysis (Section 4.1). Fix:
  trend-adjusted estimates and pre-growth conditioning.
- DA-3 MINOR [D3] Title/abstract "Coverage follows firm value rather than raising it" reads as causal about the
  provider's decision rule. Fix: "Rated firms gained value before, not after, their first ESG score" or similar.
- No CRITICAL issues: the paper already reports the failing placebo and gives two readings of the null.

## Ignored alternatives
Index inclusion (coverage bundled with index membership); disclosure mandates that make scoring feasible; vendor
backfilling.

## Observations (non-defects)
Pre-registration and the explicit failing placebo are strengths; the argument is honest about what fails.

| Dimension | Judgement |
|---|---|
| D3 argumentative_coherence | warn |
